Post

New research · Oncology
The Lancet. Oncology · 4d
ReviewThe Lancet. Oncology · 2026

Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.

Jean-Michel Hannoun-Levi, Julie A Margenthaler, Bethany Anderson … Frederick M Dirbas
Read paper
OncologyReview

Experts reached consensus on local management for most second ipsilateral breast cancer events.

Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.

Jean-Michel Hannoun-Levi … Frederick M Dirbas
The Lancet. Oncology · 2026
Background

Management of second ipsilateral breast cancer events (iBCEs) remains controversial, and there is a need to collate existing evidence and international guidance on patient selection and local treatment strategies.

Purpose

This project, endorsed by US and European surgical and radiation oncology societies, aimed to gather expert consensus on these issues.

80%
Results
80%
experts agreed on most questions about managing second breast cancer events
More results

Consensus was predefined as agreement of 75% or higher.

Panellists agreed that patient preferences are central to decision making (100%) and that a second breast-conserving therapy represents a reasonable option for selected patients (100%).

More results

Criteria associated with greater suitability for second breast-conserving therapy included an interval between surgeries of at least 60 months, low-risk accelerated partial breast irradiation classification, luminal molecular profile, and no grade 3 late toxicity related to the first breast-conserving therapy.

“
Conclusion

This international Delphi consensus offers structured guidance for the local management of second iBCE and supports shared decision making and individualised treatment planning.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
1.16%
Safety Agent gating reduced incorrect patient inclusion to 1.16% for non-small cell lung cancer trials.
Guideline
at least 20years
patients need this much follow-up because the cancer can come back many years later
AI / Informatics
32
studies exploring machine learning to predict cancer outcomes
Cohort Study
0.791
Automated whole-tumor outlines overlapped expert outlines fairly well (1.0 = perfect match)
Randomized Trial
hazard ratio 0·67
pirarubicin instillation led to a lower risk of recurrence compared to observation
Guideline
“As more new targeted agents become available and hypomethylating agent-based triplet combinations are used more widely, we fully anticipate that we will, in some years' time, write a fourth guideline on the management of AML in older patients.”
AI / Informatics
AUC = 0.939
This shows the model's excellent ability to predict ovarian cancer treatment response
Case Report
12 mm
the brain's center was pushed sideways due to severe swelling